La Veeva Commercial Summit pone el foco en la innovación digital prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Oncopeptides Partners with Veeva to Drive More Effective Engagement Ahead of First Commercial Launch
Veeva Link provides biotech with valuable market insights about top scientific and clinical leaders
News provided by
Share this article
PLEASANTON, Calif., May 17, 2021 /PRNewswire/
Veeva Systems (NYSE: VEEV) today announced a strategic partnership with Oncopeptides to support the launch of the global biotech s first commercial product. Using Veeva Link for real-time customer intelligence, Oncopeptides recently launched PEPAXTO® (melphalan flufenamide), the first anticancer peptide-drug conjugate approved by the U.S. Food and Drug Administration (FDA) for multiple myeloma. Engaging the right healthcare providers (HCPs) is key in determining how fast we can reach patients battling difficult-to-treat hematological diseases, said Mohamed H. Ladha, general manager of the U.S. business unit at Oncopeptides. Veeva Link has given our medical and commercial teams the strateg
Veeva lance une solution de contenu modulaire pour aider les entreprises à accélérer la diffusion de contenu numérique à grande échelle prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Veeva Launches Modular Content Solution to Help Companies Speed Delivery of Digital Content at Scale
BARCELONA, Spain, May 6, 2021 /PRNewswire/ Veeva Systems (NYSE: VEEV) today announced new modular content capabilities in Veeva Vault PromoMats to help life sciences marketers speed content creation, review, and distribution across channels. New enhancements to the commercial content platform include features and connectors that enable brands to quickly deliver compliant content at scale.
Veeva Pulse data shows life sciences companies created 3.5 times more digital content than print over the past year, with an average approval cycle of 21 days,
1 underscoring the need for more content, faster. By using pre-approved content modules to build sales and marketing assets, teams can accelerate legal, medical, and regulatory (MLR) reviews.